Today: 7 February 2026
Subscribe
Browse Category

NYSE:NUVB News 19 November 2025 - 11 December 2025

Nuvation Bio (NUVB) Soars After $18 Price-Target Hike – Is This High‑Growth Cancer Stock Still a Buy in 2025?

Nuvation Bio (NUVB) Soars After $18 Price-Target Hike – Is This High‑Growth Cancer Stock Still a Buy in 2025?

Nuvation Bio Inc. (NYSE: NUVB) has quietly morphed from an obscure penny stock into one of 2025’s wildest oncology stories. As of December 11, 2025, the stock is trading in the high single digits (around $7.8–$8.0), up roughly 200% year‑to‑date, following a string of clinical wins, a first drug approval, and a wave of fresh analyst upgrades. TipRanks+1 The latest jolt came today, when H.C. Wainwright raised its 12‑month price target on NUVB from $10 to $18 while reiterating a Buy / Strong Buy rating – implying well over 100% upside from recent levels. Investing.com+1 Here’s a deep dive into
11 December 2025
·····
Nuvation Bio (NUVB) Stock Soars ~50% Today as B. Riley Starts Coverage With $12 Target – 19 November 2025

Nuvation Bio (NUVB) Stock Soars ~50% Today as B. Riley Starts Coverage With $12 Target – 19 November 2025

NEW YORK, November 19, 2025 – Shares of Nuvation Bio Inc. (NYSE: NUVB) exploded higher on Wednesday after B. Riley Securities initiated coverage with a bullish rating and a $12 price target, adding fresh fuel to a rally driven by the successful launch of the company’s lung cancer drug IBTROZI™ (taletrectinib) and a blockbuster third quarter. Investing.com+2Parameter+2 As of early afternoon on November 19, 2025, NUVB was trading around $7.1–$7.2, up roughly 50% on the day from Tuesday’s close near $4.80, on extremely heavy volume. The stock’s 52‑week range has expanded from about $1.54 at the low to over $7.3
19 November 2025
····

Stock Market Today

SGX share price dips at week’s end after record profit; what investors watch next

SGX share price dips at week’s end after record profit; what investors watch next

7 February 2026
Singapore Exchange shares closed 0.4% lower at S$17.57 on Friday, despite reporting record half-year results and a higher dividend earlier in the week. Broker targets diverged after the update, with Maybank and DBS raising targets while Citi stayed bearish. Investors are watching for signs of momentum from derivatives and equity-market reforms as the next session opens Monday.
South32 share price drops 4% in ASX rout — what investors watch before results

South32 share price drops 4% in ASX rout — what investors watch before results

7 February 2026
South32 shares fell 4.1% to A$4.41 Friday as Australian miners dropped in the worst ASX session since April 2025. The S&P/ASX 200 lost 2%, erasing almost A$70 billion in value. South32’s half-year results and interim dividend decision are set for Feb. 12. Markets reopen Monday with investors watching for further volatility.
Go toTop